Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Adult T-cell leukemia
CCR4
Indium-111
Mogamulizumab
SPECT
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
02
10
2021
accepted:
03
12
2021
pubmed:
17
1
2022
medline:
5
4
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
Adult T-cell leukemia/lymphoma (ATL), caused by human T-cell lymphotropic virus type I (HTLV-1) infection, is among the most aggressive categories and has the worst prognosis among T-cell lymphomas. Mogamulizumab, an anti-CC chemokine receptor 4 (CCR 4), has been shown to be effective in the treatment of ATL; however, some ATL cases are often resistant, particularly the lymphoma-type ATL. To evaluate drug delivery in vivo and identify the distribution of CCR4-positive cells in the body, we developed a novel mogamulizumab tracer labeled with Indium-111 ( [ [ We have successfully developed a novel SPECT imaging tracer targeting CCR4, [
Identifiants
pubmed: 35034259
doi: 10.1007/s12149-021-01706-4
pii: 10.1007/s12149-021-01706-4
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CCR4 protein, human
0
Indium Radioisotopes
0
Receptors, CCR4
0
Indium-111
E9NGC49E0T
mogamulizumab
YI437801BE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-326Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K17164
Informations de copyright
© 2021. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.
doi: 10.1200/JCO.2008.16.4558
Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481–92.
doi: 10.1182/blood.V50.3.481.481
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.
doi: 10.1200/JCO.2011.37.3472
Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt. 1):3625–34.
pubmed: 14506150
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.
doi: 10.1016/S1470-2045(18)30379-6
Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11–20.
doi: 10.1093/intimm/dxu079
Antoniu SA. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010;12(6):770–9.
pubmed: 21154168
Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs. 2012;4(4):419–25.
doi: 10.4161/mabs.20996
Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293–8.
doi: 10.2165/11631090-000000000-00000
Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci. 2013;104(5):647–50.
doi: 10.1111/cas.12116
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33.
doi: 10.1200/JCO.2016.67.8250
Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4(8):644–9.
doi: 10.1158/2326-6066.CIR-15-0303
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63.
doi: 10.1200/JCO.2013.52.0924
Iwamoto FM, Schwartz J, Pandit-Taskar N, Peak S, Divgi CR, Zelenetz AD, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007;110(11):2528–34.
doi: 10.1002/cncr.23077
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma: a Children’s Oncology Group study. Clin Cancer Res. 2007;13(18 Pt. 2):5652s-s5660.
doi: 10.1158/1078-0432.CCR-07-1060
Jarrett AM, Hormuth AD, Adhikarla V, Sahoo P, Abler D, Tumyan L, et al. Towards integration of
doi: 10.1038/s41598-020-77397-0
Sato T, Coler-Reilly ALG, Yagishita N, Araya N, Inoue E, Furuta R, et al. Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy. N Engl J Med. 2018;378(6):529–38.
doi: 10.1056/NEJMoa1704827
Yamauchi J, Coler-Reilly A, Sato T, Araya N, Yagishita N, Ando H, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015;211(2):238–48.
doi: 10.1093/infdis/jiu438
Imada K, Takaori-Kondo A, Akagi T, Shimotohno K, Sugamura K, Hattori T, et al. Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo. Blood. 1995;86(6):2350–7.
doi: 10.1182/blood.V86.6.2350.bloodjournal8662350
Kondo A, Imada K, Hattori T, Yamabe H, Tanaka T, Miyasaka M, et al. A model of in vivo cell proliferation of adult T-cell leukemia. Blood. 1993;82(8):2501–9.
doi: 10.1182/blood.V82.8.2501.2501